Phase I toxicity study of methanol-extracted residue of bacillus Calmette-Guerin by the iv route

J. A. Maroun, J. R. Quesada, E. M. Hersh, J. U. Gutterman, Stephen P Richman, M. A. Schwarz, N. Parker

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Sixty-four adult patients with a variety of disseminated malignant diseases received methanol-extracted residue (MER) of bacillus Calmette-Guerin (BCG) by the iv route in doses that ranged from 0.1 to 1.25 mg/m 2. Forty patients received iv MER alone weekly and 24 patients received MER combined with chemotherapy weekly. The number of doses given to each patient ranged from one to 18, with a mean number of doses of 2.3. Fever, invariably occurring at doses of >0.5 mg/m 2, began around 3-6 hours with defervescence usually within 24 hours but lasting as long as 5 days. Chills, malaise, nausea and/or vomiting, and headaches were frequent side effects independent of dose. The large majority of patients had a good tolerance necessitating only symptomatic therapy. No difference in toxicity was found between the two groups analyzed. Eleven patients (17.2%) had more serious toxic effects; eight patients (13.7%) developed bilateral pulmonary infiltrates after one to 18 doses suggestive of granulomatous disease. This was not dose-related but correlated with history of prior BCG treatment or presence of a positive PPD skin test. The abnormality resolved spontaneously upon discontinuation of MER, usually within 4-6 weeks. There was one case of acute urticaria reaction controlled with antihistaminics. There was also one case each of acute erythrodermic rash and bullous dermatosis with acute vasculitis in the skin controlled with oral glucocorticoids. There were no major life-threatening toxic reactions and no long-term morbidity induced by iv MER. No definite tumor responses were documented. It appears that iv MER is a safe modality of treatment which should be investigated in phase II trials. The dose should be reduced in patients with a history of prior BCG or a positive PPD skin test. A dose of 0.1 mg is recommended for these patients and a dose of 0.5 mg/m 2 is recommended for the others.

Original languageEnglish
Pages (from-to)1781-1786
Number of pages6
JournalCancer Treatment Reports
Volume63
Issue number11-12
StatePublished - Dec 1 1979
Externally publishedYes

Fingerprint

Mycobacterium bovis
Methanol
Poisons
Tuberculin
Skin Tests
Vesiculobullous Skin Diseases
Chills
Urticaria
Vasculitis
Exanthema
Nausea
Glucocorticoids
Vomiting
Headache
Fever
Therapeutics
Morbidity
Drug Therapy
Lung
Skin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Maroun, J. A., Quesada, J. R., Hersh, E. M., Gutterman, J. U., Richman, S. P., Schwarz, M. A., & Parker, N. (1979). Phase I toxicity study of methanol-extracted residue of bacillus Calmette-Guerin by the iv route. Cancer Treatment Reports, 63(11-12), 1781-1786.

Phase I toxicity study of methanol-extracted residue of bacillus Calmette-Guerin by the iv route. / Maroun, J. A.; Quesada, J. R.; Hersh, E. M.; Gutterman, J. U.; Richman, Stephen P; Schwarz, M. A.; Parker, N.

In: Cancer Treatment Reports, Vol. 63, No. 11-12, 01.12.1979, p. 1781-1786.

Research output: Contribution to journalArticle

Maroun, JA, Quesada, JR, Hersh, EM, Gutterman, JU, Richman, SP, Schwarz, MA & Parker, N 1979, 'Phase I toxicity study of methanol-extracted residue of bacillus Calmette-Guerin by the iv route', Cancer Treatment Reports, vol. 63, no. 11-12, pp. 1781-1786.
Maroun JA, Quesada JR, Hersh EM, Gutterman JU, Richman SP, Schwarz MA et al. Phase I toxicity study of methanol-extracted residue of bacillus Calmette-Guerin by the iv route. Cancer Treatment Reports. 1979 Dec 1;63(11-12):1781-1786.
Maroun, J. A. ; Quesada, J. R. ; Hersh, E. M. ; Gutterman, J. U. ; Richman, Stephen P ; Schwarz, M. A. ; Parker, N. / Phase I toxicity study of methanol-extracted residue of bacillus Calmette-Guerin by the iv route. In: Cancer Treatment Reports. 1979 ; Vol. 63, No. 11-12. pp. 1781-1786.
@article{28fa02589e76428fb2e642e3cabcdf1b,
title = "Phase I toxicity study of methanol-extracted residue of bacillus Calmette-Guerin by the iv route",
abstract = "Sixty-four adult patients with a variety of disseminated malignant diseases received methanol-extracted residue (MER) of bacillus Calmette-Guerin (BCG) by the iv route in doses that ranged from 0.1 to 1.25 mg/m 2. Forty patients received iv MER alone weekly and 24 patients received MER combined with chemotherapy weekly. The number of doses given to each patient ranged from one to 18, with a mean number of doses of 2.3. Fever, invariably occurring at doses of >0.5 mg/m 2, began around 3-6 hours with defervescence usually within 24 hours but lasting as long as 5 days. Chills, malaise, nausea and/or vomiting, and headaches were frequent side effects independent of dose. The large majority of patients had a good tolerance necessitating only symptomatic therapy. No difference in toxicity was found between the two groups analyzed. Eleven patients (17.2{\%}) had more serious toxic effects; eight patients (13.7{\%}) developed bilateral pulmonary infiltrates after one to 18 doses suggestive of granulomatous disease. This was not dose-related but correlated with history of prior BCG treatment or presence of a positive PPD skin test. The abnormality resolved spontaneously upon discontinuation of MER, usually within 4-6 weeks. There was one case of acute urticaria reaction controlled with antihistaminics. There was also one case each of acute erythrodermic rash and bullous dermatosis with acute vasculitis in the skin controlled with oral glucocorticoids. There were no major life-threatening toxic reactions and no long-term morbidity induced by iv MER. No definite tumor responses were documented. It appears that iv MER is a safe modality of treatment which should be investigated in phase II trials. The dose should be reduced in patients with a history of prior BCG or a positive PPD skin test. A dose of 0.1 mg is recommended for these patients and a dose of 0.5 mg/m 2 is recommended for the others.",
author = "Maroun, {J. A.} and Quesada, {J. R.} and Hersh, {E. M.} and Gutterman, {J. U.} and Richman, {Stephen P} and Schwarz, {M. A.} and N. Parker",
year = "1979",
month = "12",
day = "1",
language = "English",
volume = "63",
pages = "1781--1786",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "11-12",

}

TY - JOUR

T1 - Phase I toxicity study of methanol-extracted residue of bacillus Calmette-Guerin by the iv route

AU - Maroun, J. A.

AU - Quesada, J. R.

AU - Hersh, E. M.

AU - Gutterman, J. U.

AU - Richman, Stephen P

AU - Schwarz, M. A.

AU - Parker, N.

PY - 1979/12/1

Y1 - 1979/12/1

N2 - Sixty-four adult patients with a variety of disseminated malignant diseases received methanol-extracted residue (MER) of bacillus Calmette-Guerin (BCG) by the iv route in doses that ranged from 0.1 to 1.25 mg/m 2. Forty patients received iv MER alone weekly and 24 patients received MER combined with chemotherapy weekly. The number of doses given to each patient ranged from one to 18, with a mean number of doses of 2.3. Fever, invariably occurring at doses of >0.5 mg/m 2, began around 3-6 hours with defervescence usually within 24 hours but lasting as long as 5 days. Chills, malaise, nausea and/or vomiting, and headaches were frequent side effects independent of dose. The large majority of patients had a good tolerance necessitating only symptomatic therapy. No difference in toxicity was found between the two groups analyzed. Eleven patients (17.2%) had more serious toxic effects; eight patients (13.7%) developed bilateral pulmonary infiltrates after one to 18 doses suggestive of granulomatous disease. This was not dose-related but correlated with history of prior BCG treatment or presence of a positive PPD skin test. The abnormality resolved spontaneously upon discontinuation of MER, usually within 4-6 weeks. There was one case of acute urticaria reaction controlled with antihistaminics. There was also one case each of acute erythrodermic rash and bullous dermatosis with acute vasculitis in the skin controlled with oral glucocorticoids. There were no major life-threatening toxic reactions and no long-term morbidity induced by iv MER. No definite tumor responses were documented. It appears that iv MER is a safe modality of treatment which should be investigated in phase II trials. The dose should be reduced in patients with a history of prior BCG or a positive PPD skin test. A dose of 0.1 mg is recommended for these patients and a dose of 0.5 mg/m 2 is recommended for the others.

AB - Sixty-four adult patients with a variety of disseminated malignant diseases received methanol-extracted residue (MER) of bacillus Calmette-Guerin (BCG) by the iv route in doses that ranged from 0.1 to 1.25 mg/m 2. Forty patients received iv MER alone weekly and 24 patients received MER combined with chemotherapy weekly. The number of doses given to each patient ranged from one to 18, with a mean number of doses of 2.3. Fever, invariably occurring at doses of >0.5 mg/m 2, began around 3-6 hours with defervescence usually within 24 hours but lasting as long as 5 days. Chills, malaise, nausea and/or vomiting, and headaches were frequent side effects independent of dose. The large majority of patients had a good tolerance necessitating only symptomatic therapy. No difference in toxicity was found between the two groups analyzed. Eleven patients (17.2%) had more serious toxic effects; eight patients (13.7%) developed bilateral pulmonary infiltrates after one to 18 doses suggestive of granulomatous disease. This was not dose-related but correlated with history of prior BCG treatment or presence of a positive PPD skin test. The abnormality resolved spontaneously upon discontinuation of MER, usually within 4-6 weeks. There was one case of acute urticaria reaction controlled with antihistaminics. There was also one case each of acute erythrodermic rash and bullous dermatosis with acute vasculitis in the skin controlled with oral glucocorticoids. There were no major life-threatening toxic reactions and no long-term morbidity induced by iv MER. No definite tumor responses were documented. It appears that iv MER is a safe modality of treatment which should be investigated in phase II trials. The dose should be reduced in patients with a history of prior BCG or a positive PPD skin test. A dose of 0.1 mg is recommended for these patients and a dose of 0.5 mg/m 2 is recommended for the others.

UR - http://www.scopus.com/inward/record.url?scp=0018597367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018597367&partnerID=8YFLogxK

M3 - Article

C2 - 393379

AN - SCOPUS:0018597367

VL - 63

SP - 1781

EP - 1786

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 11-12

ER -